Cardiology Xagena
The Food and Drug Administration ( FDA ) issued a public health advisory, a patient information sheet and a corresponding healthcare professional information sheet further explaining the identified ri ...
A two-year study demonstrated that Rosuvastatin ( Crestor ) reversed plaque build-up in the arteries of patients with evidence of coronary artery disease. This is the first time a statin has demon ...
A study using ultrasound technology has found that Rosuvastatin ( Crestor ), a cholesterol-lowering drug, is also effective at halting early changes in the blood vessels that can lead to atheroscleros ...
Findings from the ASTEROID trial showed that patients with heart disease who took the maximum dose of Rosuvastatin ( 40 mg per day; Crestor ) for 24 months and achieved on average LDL cholesterol leve ...
A study looking at the data of thousands of patients who suffered myocardial infarctions has suggested treatment with high-potency statins offers a significantly improved chance of survival compared t ...
A study has determined all-cause mortality in patients with a first myocardial infarct who were treated with Simvastatin ( Zocor ) compared with high-potency statin and Simvastatin / Ezetimibe ( Vytor ...
Current guidelines do not explicitly recommend statin use in heart failure ( HF ). Relatively low numbers of atherothrombotic events among patients with heart failure, in the context of their elevated ...
Recent trials have shown a reduction in the risk of major adverse cardiac events ( MACE ) with Simvastatin and Ezetimibe ( Vytorin ) therapy in patients with acute coronary syndrome. The potential be ...
A high loading dose of Atorvastatin ( Lipitor ) has been confirmed to reduce postprocedural events in patients undergoing percutaneous coronary intervention ( PCI ). In this study, researchers sough ...
Heart disease patients with symptomatic COVID-19 are often treated with Nirmatrelvir - Ritonavir ( Paxlovid ) to prevent progression to severe disease; however, it can interact with some previously pr ...
